Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Myeloid 3Classical hematology 2Other hematologic neoplasm 1

Conditions

Primary Myelofibrosis 3Myelodysplastic Syndromes 3Anemia 3beta-Thalassemia 2Myeloproliferative Disorders 2Leukemia, Myeloid, Acute 1

Interventions

ruxolitinib 28navitoclax 6Azacitidine 511-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 4parsaclisib 3luspatercept 3itacitinib 3givinostat hydrochloride 3givinostat 3fedratinib 3INCB039110 3selinexor 2pomalidomide 2imetelstat 2bomedemstat 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2LY2784544 2INCB057643 2GRN163L peptide 2venetoclax 1triciribine 1tagraxofusp 1spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1rucaparib 1ridaforolimus 1quizartinib 1pelcitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Primary Myelofibrosis × luspatercept × Clear all
NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01688011 2025-07-03

Connect® Myeloid Disease Registry

Celgene

Terminated
2,013 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03194542 2023-08-24

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Celgene

Phase 2 Completed
95 enrolled 32 charts
Classical hematologyMyeloid

Anemia, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡